BioDelivery CEO: opioid dependence treatment ready to take off

BioDelivery Sciences stock has surged in the past month because investors realize the potential for Bunavail, its recently FDA approved treatment for opioid dependency, says the company's CEO Dr. Mark Sirgo. Sirgo says the ability of Bunavail to sti